



Medicines & Healthcare products Regulatory Agency

MHRA Freedom of Information Act (FOIA) request Disclosure Log index

This document contains reference details for all FOIA requests which have been answered in full or in part, or for which the agency held no information.

It is a fully searchable PDF which will produce a list of all requests containing the chosen search term.

If you wish to see the original request and subsequent agency reply, please send an email headed "Disclosure Log request" to:

FOI_policy@mhra.gsi.gov.uk

As long as it is headed correctly it will not be treated as a new FOIA request. The identity of the original requester will be redacted.

<i>FOI no</i>	<i>Subject</i>	<i>Date reply sent</i>	<i>Result of request</i>
15/149	Various questions about the agency's IT.	17 April 2015	Answered - in part
15/150	The Periodic Safety Update report filed in the period from 2012 until now for medicinal products containing alendronate as the active substance. The concerned medicinal products carry the brand names: Fosamax, Steovess and Binosto.	14 April 2015	007a. Not held (not our info/not collected)
15/153	Request for MHRA PV Inspection Reports for Baxter Healthcare Janssen-Cilag International NV Sandoz Limited AbbVie Eisai MSD-SP Mercury Pharma (formerly Goldshield) Novartis Pharma	30 April 2015	Answered - in part
15/154	Information regarding MHRA Software Licenses	17 April 2015	Answered - in part
15/155	Risk Management Plan for Cipramil Drops 40mg/ml (PL 0458/0071)	14 April 2015	007a. Not held (not our info/not collected)
15/158	Over the past five years, how much money has been spent by the agency and committees in total regulating homeopathic preparations?	21 April 2015	Answered - in part
15/159	Request for letter from Bayer to Treasury solicitors related to primodos	30 April 2015	Answered - in part
15/160	Obtaining leaflets in alternative formats	21 April 2015	Answered - in full
15/161	Current inspection reports for the following UK facilities - • Exova - Newbridge • Select Pharma - Stirling • Hologic - West Lothian	05 May 2015	Answered - in part
15/163	All animal tests relating to Primodos.	28 April 2015	Answered - in part
15/165	Information regarding MHRA Software Licenses	17 April 2015	Answered - in part
15/166	Redacted copies of MHRA GMDP Inspection Reports issued in the last 3 years for MGS Laboratories Ltd at various addresses	06 May 2015	Answered - in part
15/167	Redacted copies of MHRA GMDP Inspection Reports issued in the last 3 years for ALS Food and Pharmaceutical at various addresses	06 May 2015	Answered - in part
15/168	Animal studies related to primodos	28 April 2015	Answered - in part
15/169	Information regarding the Mplus X lens	28 April 2015	Answered - in full
15/170	Evidence which alludes to women being unable to have intercourse before their mesh implants	10 April 2015	Answered - in full

<i>FOI no</i>	<i>Subject</i>	<i>Date reply sent</i>	<i>Result of request</i>
15/172	Latest GMP inspection report for Melbourn Scientific	06 May 2015	Answered - in part
15/174	Agency adherence to Civil Service Code and questions around propriety, confidentiality, whistleblowing etc	08 May 2015	Answered - in full
15/177	What information do you hold on studies into any connection, implicit or otherwise, between depression and mental health issues and the drug Roaccutane?	28 April 2015	Answered - in full
15/178	A list of suppliers providing outsourced ICT Services to the agency	01 May 2015	Answered - in full
15/179	Request to identify what medical device was referred to by an MHRA staff member - TVT mesh related	20 April 2015	Answered - in full
15/182	The list of the 2015 (conducted and planned) GCP MHRA inspections.	07 May 2015	Answered - in full
15/184	Adverse vaccine reactions being reported between 2005 and 2015	14 May 2015	Answered - in full
15/186	Roaccutane use	15 May 2015	Answered - in part
15/187	Phase 1 Clinical Trial Statistics	07 May 2015	Answered - in full
15/188	Identity of an MDLO	30 April 2015	007a. Not held (not our info/not collected)
15/189	1. How can one search for a registered product in UK without going through the monthly registered product list? 2. The registration and PAR of the ciclopirox shampoo Sebiprox 1%	01 May 2015	007a. Not held (not our info/not collected)
15/190	Various questions relating to Roaccutane and adverse incidents	18 May 2015	Answered - in part
15/191	A copy of the last inspection report for various organisations.	19 May 2015	Answered - in part
15/192	Various questions about inspections of Biotech, generic, pharmaceutical companies, CROs whose clinical trial investigation sites have been inspected and the outcomes.	18 May 2015	Answered - in part
15/193	MHRA 2014 studies related to primodos	28 April 2015	Answered - in part
15/194	A list of products that have been granted authorisation under Article 16.2	15 May 2015	Answered - in full
15/195	Which senior MHRA staff have financial interests in the pharmaceutical industry?	18 May 2015	Answered - in full
15/197	Enquiry about the product Ecolab chlorhexidine 2% in 70% IPA.	20 May 2015	Answered - in full
15/199	The reports showing the results of the follow-up study dating from 1970-1977 and that of 1977-1984 in respect of Congenital Abnormalities	07 May 2015	007b. Not held (disposed of/couldn't locate)
15/201	Various questions about nominated signatories to the ABPI Code registered with the MHRA.	13 May 2015	Answered - in full
15/204	Reports on symptoms relating to HPV, HPV Cervarix and other vaccines.	22 May 2015	Answered - in full
15/205	How many girls have been followed up after reporting events categorised as Serious following HPV vaccination (in years 2009 to 2013).	22 May 2015	Answered - in full

<i>FOI no</i>	<i>Subject</i>	<i>Date reply sent</i>	<i>Result of request</i>
15/206	Results of GcMAF testing.	21 May 2015	Answered - in full
15/207	Various questions on the Early Access to Medicines Scheme.	27 May 2015	Answered - in full
15/208	Copy of the most recent MHRA inspection report for FDAS, Food and Drug Analytical Services.	27 May 2015	Answered - document/s refused
15/209	Copy of the risk management plan for Xeloda (capecitabine, Roche).	06 May 2015	007a. Not held (not our info/not collected)
15/211	Legal documents sent by named lawyers to named MHRA staff.	01 May 2015	007a. Not held (not our info/not collected)
15/212	Inspection related information concerning specific pharmacovigilance service providers.	01 June 2015	Answered - in part
15/213	Various questions about primodos.	28 May 2015	007b. Not held (disposed of/couldn't locate)
15/214	The latest version of the Risk Management Plan (RMP) of Neupogen.	29 May 2015	Answered - in part
15/215	Various questions about the MHRA Contact Centre and Inbound Network Services.	22 May 2015	Answered - in part
15/216	Statistics on Serious Adverse Effects and Reactions suffered as a consequence of clinical trials.	01 June 2015	Answered - in part
15/217	Summary of the RMP for the reference medicinal product vancomycin.	14 May 2015	007a. Not held (not our info/not collected)
15/219	Gas and Electricity supply questions.	11 May 2015	Answered - in part
15/220	Various ICT information.	11 May 2015	Answered - in part
15/221	Public Assessment Report of the product Physeptone® (Methadone).	08 May 2015	007a. Not held (not our info/not collected)
15/222	All decisions concerning variations to marketing authorizations in the form of switches of prescription status from Rx to OTC.	20 May 2015	Answered - in part
15/224	A copy of the risk management plan for Procoralan (ivabradine).	15 May 2015	007a. Not held (not our info/not collected)
15/225	The last MHRA inspection report for BOC HOLBROOK.	28 May 2015	Answered - in part
15/226	Naproxen - Reclassification Rx to P to GSL	15 May 2015	Answered - in part
15/229	1. Sativex assessment report.	08 June 2015	Answered - in full
	2. DCP or MRP procedures, where the MHRA was RMS or CMS for products containing the herbal actives: St Johns wort; Echinacea; Valerian; Saw palmetto; Senna		
15/232	Request from student for an agency audit report	11 June 2015	Answered - in part
15/233	The number of adverse drug reactions for antipsychotics, and in particular Quetiapine, reported within the last two years.	28 May 2015	007a. Not held (not our info/not collected)

<i>FOI no</i>	<i>Subject</i>	<i>Date reply sent</i>	<i>Result of request</i>
15/234	Request from student for an agency inspection report	11 June 2015	Answered - in part
15/235	Correspondence regarding Teva Levothyroxine.	13 July 2015	Answered - in part
15/236	Inspection report relating to Flamingo Pharmaceuticals Limited, India, case ref. Insp GMP 22674/30580-0006.	05 June 2015	Answered - in part
15/237	All uses made by hospitals of the Stryker 11AGB system in hip replacements since 2000 and copies of all adverse reactions	16 June 2015	Answered - document/s refused
15/241	What was the legal basis for granting licence (PL00014/0593) - Boots Blocked Nose Relief 12mg Capsules (PL00014/0593)	22 May 2015	Answered - in full
15/243	Questions regarding the licensing status of Natural Dessicated Thyroid	09 June 2015	007a. Not held (not our info/not collected)
15/244	Questions regarding importing "Decadron" as an unlicensed medicinal product	22 June 2015	Answered - in full
15/245	The first and any subsequent release date (into the public domain) of the Public Assessment Report for product PL42701/0001.	28 May 2015	Answered - in full
15/246	List of products the MHRA have granted permission to import as an unlicensed medicinal product in the years 2010 and 2011	22 June 2015	Answered - in full
15/247	ISE 15-006 - SPCs for PL 17736/0119 Dexamethasone 500 microgram Tablets	19 June 2015	Answered - in full
15/249	Queries regarding MHRA's use of mobile phones	05 June 2015	Answered - in part
15/250	A report for all Suspected Serious Adverse Events concerning Gardasil	23 June 2015	Answered - in full
15/253	Details of the number of adverse drug reactions for antipsychotics, by hospitals within the last two years	25 June 2015	Answered - in full
15/255	A copy of GPvP Inspection Report of Symogen Ltd	22 June 2015	Answered - in part
15/256	Information on ICT	24 June 2015	Answered - in full
15/258	Further questions regarding approval of antipsychotics.	01 July 2015	007b. Not held (disposed of/couldn't locate)
15/260	Issues about medications been derived from aborted foetus cells.	26 June 2015	Answered - in part
15/262	Adverse reactions to HPV vaccine.	30 June 2015	Answered - in full
15/264	Public Assessment Report for MIRENA	11 June 2015	007a. Not held (not our info/not collected)
15/265	Various questions about Cytaccon 50mcg Tablets	08 June 2015	007a. Not held (not our info/not collected)
15/266	Authorisation, dossier and clinical data for Welldorm Elixir; PL 23138/0016.	08 June 2015	007b. Not held (disposed of/couldn't locate)
15/267	Authorisation, dossier and clinical data for Welldorm Tablets 707mg PL No: PL 23138/0015.	08 June 2015	007b. Not held (disposed of/couldn't locate)

<i>FOI no</i>	<i>Subject</i>	<i>Date reply sent</i>	<i>Result of request</i>
15/268	Summary of safety concerns from the RMPs for Xenical (orlistat), Alli (orlistat) and Pantozol Control (pantoprazole).	17 June 2015	007a. Not held (not our info/not collected)
15/271	How many case reports for HPV vaccine	06 July 2015	Answered - in full
15/272	Public assessment report for Methotrexate 2.5mg tablets UK/H/3956/001.	11 June 2015	Answered - document/s refused
15/273	Details of IT contracts	30 June 2015	Answered - in part
15/274	Information regarding any art owned by the agency	10 June 2015	Answered - in full
15/275	licences for Indapamide 1.5mg immediate release tablets	22 June 2015	Answered - in part
15/277	Drug safety advice notice and all published documents relating to Entonox (Jan 2009 and Feb 2011)	08 July 2015	Answered - in part
15/278	Application for licence and public assessment report for PLPI 19065/0464, 08/01/2015, Ecosse Pharmaceuticals Ltd: Equasym XL 10 mg modified-release capsules, hard methylphenidate hydrochloride 10 mg	18 June 2015	Answered - in part
15/279	Details of FOI requests re Copaxone (glatiramer acetate; UK licence no: PL 10921/0023) from 01 April 2003 to 10/06/2015	17 June 2015	Answered - in part
15/282	The GMP Inspection report on Penn Pharmaceutical Services Ltd (MIA(IMP) 4351), re Inspection on 28 Oct 2013.	03 July 2015	Answered - in part
15/283	Product licence data for Hydrocortisone 0.5% Cream , Hydrocortisone 1% Cream and Hydrocortisone 2.5% Cream.	10 July 2015	Answered - in part
15/288	The last agency Inspection report (2012) for Reliance Life Sciences , Maharashtra, India.	30 June 2015	Answered - in part
15/289	Anonymised extracts of incident reports between Oct 2010 & Oct 2011 re Philips Integris v5000 Cardiac System	08 July 2015	Answered - in part
15/290	Feedback on tender for lift maintenance.	18 June 2015	Answered - in full
15/292	Asks if a bioequivalence study was provided to support an application for Mebeverine 135 mg film-coated tablets PL 00289/0095. If so confirm reference product used in study and a summary of the bio study results.	10 July 2015	007b. Not held (disposed of/couldn't locate)
15/307	Analysis by reporter type (including 'patients & carers') of yellow cards submitted in last three years. Same analysis specifically regarding HPV vaccine.	15 July 2015	Answered - in full
15/308	GMP audit report for ILS Ltd, Derby conducted 13th – 15th April 2014	01 July 2015	Answered - in part
15/309	The latest copy of the UK Abacavir/ Lamivudine innovator educational material which includes a patient alert card highlighting 'Allergic reaction to abacavir (ABC hypersensitivity reaction)'. 1. Licence Authorisation Number UK MIA MIA 4394 D D D LIMITED / FLEET LABORATORIES LIMITED SITE ID : 3787 2. Licence Authorisation Number UK MIA 2021	15 July 2015	Answered - in part
15/310	The last GMP inspection reports for: 1. Licence Authorisation Number UK MIA MIA 4394 D D D LIMITED / FLEET LABORATORIES LIMITED SITE ID : 3787 2. Licence Authorisation Number UK MIA 2021	03 July 2015	Answered - in part

<i>FOI no</i>	<i>Subject</i>	<i>Date reply sent</i>	<i>Result of request</i>
	Fuchs Lubricant (UK) Plc, HANLEY		
15/314	Results from MHRA inspections in UK from 01/09/2014 to date for GMP and GDP and a list of planned inspections for 2014/15.	03 July 2015	Answered - in part
15/319	Requests copies of responses to requests: 13/600, 13/608, 13/620, 14/059, 14/161, 14/212, 14/239, 14/314, 14/315, 14/338, 14/355, 14/481 and 15/107.	15 July 2015	Answered - in part
15/320	Information about online pharmacies and doctors contacted as their websites breached agency guidelines on sale of prescription medicines.	22 July 2015	Answered - in part
15/321	How many registered online pharmacies and doctors have received letters in the past 12 months regarding their website breaking some form of MHRA guidelines.	22 July 2015	Answered - in part
15/322	The last 20 inspection reports between Jan and Mar 2015.	23 July 2015	Answered - in part
15/324	The no. of suspected adverse events reported regarding Cervarix, Gardasil and other which were classed as "additional information".	27 July 2015	Answered - in full
15/325	Further information about medications been derived from aborted foetus cells.	14 July 2015	Answered - in full
15/326	Copy of the Risk Management Plan produced by the innovator of Loperamide in the UK.	27 July 2015	007a. Not held (not our info/not collected)
15/327	Request for pharmacovigilance inspection reports	30 June 2015	Answered - in part
15/328	Which form of nitrofurantoin is used (monohydrate or anhydrous in manufacture of Furdantin 25mg/5ml Suspension PL 12762/00055 and Nitrofurantoin 100mg capsules PL12762/0049.	29 July 2015	Answered - in part
15/329	Yellow card data for the following vaccines: Pediacef, Prevenar 13, Rotarix, Bexsero, Neisvac C, Menjugate, Priorix, MMRVAXPRO, Fluenz tetra, Gardasil.	29 July 2015	Answered - in full
15/330	Reference product data for Testosterone Gel 1%	09 July 2015	Answered - in part
15/331	Requests name individual as used in court proceedings lodged by agency.	24 July 2015	Answered - in full
15/332	20 of the major pharmacovigilance inspection findings concerning "ICSR management" in the period 01-Apr-2013 to 31-Mar-2014	28 July 2015	Answered - in part
15/333	UKPAR for Nurofen Back Pain Licence PL 00063/0378; first date of approval 19/9/1997	16 July 2015	Answered - in part
15/335	Queries re contracts/provision of Microsoft Office training	09 July 2015	Answered - in part
15/336	Reference product data for Testosterone Gel 1%.	30 July 2015	Answered - in part
15/339	All MHRA pharmacovigilance inspection reports for inspections closed between January 2015 and June 2015.	29 July 2015	Answered - in part

<i>FOI no</i>	<i>Subject</i>	<i>Date reply sent</i>	<i>Result of request</i>
15/340	Copies of GMP inspection reports completed in last 2yrs, for 20 named sites.	03 August 2015	Answered - in part
15/341	Last audit of Quay Pharmaceuticals Ltd	03 August 2015	Answered - in part
15/343	A copy of the Clinical Expert Report/Clinical Overview for Protamine.	21 July 2015	007b. Not held (disposed of/couldn't locate)
15/344	A copy of the 'Summary of Clinical Safety' (CTD Module 2.7.4) for the original submission of Requip film-coated tablets	30 July 2015	Answered - in part
15/345	Data for Reference product of Flagyl-S 200mg/5ml oral suspension.	03 August 2015	007b. Not held (disposed of/couldn't locate)
15/347	Copies of a clinical trial in Yugoslavia in 1988.	05 August 2015	007b. Not held (disposed of/couldn't locate)
15/349	Most recent MHRA PV inspection reports for: Gilead, Synthon, Merck, Meiji Seika Kaisha Ltd, Menarini.	03 August 2015	Answered - in part
15/351	Leucomax report(s) on embryo-foetal development and pre- and postnatal development studies in non-human primates.	04 August 2015	007a. Not held (not our info/not collected)
15/353	Data regarding Thiamine 300mg tablets PL No: 00010/0312.	15 July 2015	Answered - in part
15/356	Environmental Risk Assessment (ERA) for Fucibet® Lipid Cream (Fusidic Acid 2%, Betamethasone 0.1%) PL 00043/0218.	06 August 2015	Answered - in part
15/357	Asks how decisions to commission drugs, particularly for diabetes, are influenced by cost; and how this changes dependent upon geographical location	13 July 2015	007a. Not held (not our info/not collected)
15/358	A list of all panel members who will be sitting on the Primodos panel in August 2015.	10 August 2015	007a. Not held (not our info/not collected)
15/359	Copy of the most recent Risk Management Plan for the reference medicine for Colchicine Tablets in the UK	10 August 2015	Answered - in part
15/360	No. of Marketing Authorizations have been granted to 'e-liquids' used with refillable e-cigarettes; also links to PARs relating to such liquids and the devices they fill.	23 July 2015	Answered - in full
15/361	Various questions on PIP Breast implants, including ALCL reports, members of the DEAC and their Declarations of Interests, actions taken by TUV and updates on Adverse Event reports.	13 August 2015	Answered - in full
15/365	MHRA Audit report for Marksans Pharma Ltd.	10 August 2015	Answered - in part
15/366	Information on Facilities Management (maintenance, cleaning, security and catering services).	31 July 2015	Answered - in part
15/367	CSM minutes Sub Committee on Adverse Reactions meetings 1-6 from 1979.	24 July 2015	007a. Not held (not our info/not collected)
15/369	Information on Recycling and waste support and maintenance contracts.	23 July 2015	Answered - in part

<i>FOI no</i>	<i>Subject</i>	<i>Date reply sent</i>	<i>Result of request</i>
15/373	Details of registered online UK pharmacies and online doctors contacted by the MHRA as their website was in breach of MHRA guidelines.	18 August 2015	Answered - in part
15/374	In 2015, what should a member of the public do if they have been unable to find out why some volunteers became anxious and ill during and after a drug trial?	13 August 2015	Answered - in full
15/375	The number of occasions on which the MHRA has been notified of the import of NDT.	17 August 2015	Answered - in full
15/379	Further information about medications been derived from aborted foetus cells.	12 August 2015	Answered - in part
15/380	Various questions about all non-traditional actives (API) registered in the UK and their manufacturers.	07 August 2015	Answered - in part
15/381	Evidence of name used by individual in court proceedings lodged by agency	29 July 2015	Answered - in full
15/382	A copy of the first Product Licence for the vaccine Pluserix manufactured by GSK and any subsequent amendments and copy of the first Product licence granted for Immravax manufactured by Merieux.	14 August 2015	Answered - in part
15/385	Various questions about Maternity/Paternity leave.	05 August 2015	Answered - in full
15/386	Various questions, including contract information, on Lines, Minutes, Broadband and WAN.	24 August 2015	Answered - in part
15/388	The last two Pharmacovigilance inspection reports for Amgen in Cambridge and Valeant in St. Leonards-On-Sea.	21 August 2015	Answered - in part
15/389	RMP for Bosentan.	25 August 2015	Answered - in part
15/391	How many of the 13 fatalities reported via the Yellow Card system for Citalopram have the MHRA followed up?	25 August 2015	Answered - in full
15/392	Old MHRA advertising investigations into Pradaxa and Botox.	24 August 2015	Answered - in part
15/393	Risk Management Plan for Paracetamol 500mg tablets granted to Beximco Pharma UK Ltd.	05 August 2015	007a. Not held (not our info/not collected)
15/394	PARs for Prostag SR, 3.75mg and Prostag 3, 11.25mg.	03 August 2015	007a. Not held (not our info/not collected)
15/396	Request for Innovator's summary of the RMP, valsartan.	12 August 2015	Answered - in part
15/397	The names of any erectile dysfunction medicines currently approved by the MHRA for use in the UK.	07 August 2015	Answered - in full
15/399	No. of adverse incidents reported regarding mesh for Stress Urinary Incontinence and Pelvic Organ prolapse for the first half of 2015.	28 August 2015	Answered - in full
15/400	The amount MHRA pays to the Confederation of British Industry and its subsidiaries.	12 August 2015	Answered - in full
15/401	GDP Inspection report for Special Products Limited.	28 August 2015	Answered - in part
15/402	The amount BP pays to the Confederation of British Industry and its subsidiaries.	27 August 2015	007a. Not held (not our info/not collected)

<i>FOI no</i>	<i>Subject</i>	<i>Date reply sent</i>	<i>Result of request</i>
15/403	Further request for patient IDs relating to FOI 08/330 and for a copy of the redacted material.	08 September 2015	Answered - in part
15/404	The number of reports received by the MHRA of adverse sexual effects caused by SSRIs.	08 September 2015	Answered - in full
15/405	The 'follow-up' rates for reported adverse reactions that have come via the Yellow Card reporting system for years 2011 to 2015.	08 September 2015	Answered - in full
15/407	The amount MHRA pays to the Confederation of British Industry and its subsidiaries.	12 August 2015	Answered - in full
15/408	Various questions on Paracetamol.	02 September 2015	Answered - in part
15/410	Redacted copies of MHRA GMDP inspection reports of the following companies:	09 September 2015	Answered - in part
	<ol style="list-style-type: none"> 1. Emcure Pharmaceuticals Limited 2. RPG Life Sciences Limited 3. Flamingo Pharmaceuticals Limited 4. Square Pharmaceuticals Limited 5. Kopran Limited 6. RA Chem Pharma Limited 7. Piramal Healthcare Limited 		
15/411	the Public assessment report of following product:	17 August 2015	Answered - in part
	<p>Product Name: Memantine 20mg Film-coated tablets</p> <p>MA No: PL42357/0150</p> <p>MA Holder: Amneal Pharma Europe Limited</p>		
15/412	Re: the Mirena Coil:	01 September 2015	Answered - in part
	<ol style="list-style-type: none"> 1) No. of reports of adverse side effects received by the MHRA to date broken down by year and type of concern. 2) Total number of UK women fitted with the device by year. 3) Total number of women fitted with the device, in the UK, 1995 to date. 		
15/415	How many suicides and psychiatric disorders reported in the agency's DAP for Mefloquine have been investigated by the agency?	15 September 2015	Answered - in full
15/416	Questions regarding the history of marketing authorisations for Zyvox, linezolid and gabriox.	11 September 2015	Answered - in part
15/419	Various information relating to an adverse event concerning Flowtron compression device.	18 September 2015	Answered - in part
15/423	Further questions regarding the history of marketing authorisations for Zyvox and linezolid, including assessment reports and EU MS comments.	23 September 2015	Answered - in part

<i>FOI no</i>	<i>Subject</i>	<i>Date reply sent</i>	<i>Result of request</i>
15/425	Public Assessment Report for Tetralysal 300mg Hard Capsules.	03 September 2015	007a. Not held (not our info/not collected)
15/426	Various information about Prednesol Tablets 5 mg / Soluble Prednisolone Tablets 5 mg.	25 September 2015	Answered - in part
15/427	Various information about Sinepin Capsules 50 mg.	24 September 2015	Answered - in part
15/428	Data from the product dossier justifying safety and efficacy of Gliclazide Tablets 80mg BP.	07 September 2015	Answered - in part
15/429	Asks for evidence to support statement regarding cannabis found on https://petition.parliament.uk/petitions/104349)	22 September 2015	007a. Not held (not our info/not collected)
15/430	The PAR and EU RMP for Xentevix 350 solution for injection, PL 12308/0011, MAH Guerbet.	03 September 2015	007a. Not held (not our info/not collected)
15/431	Details of incidents reports relating to dental amalgam usage and monitoring undertaken; and specifically reports since 2004 relating to Birmingham residents who were born between 1950 and 1960.	28 September 2015	Answered - in part
15/432	re: Potters Bar: Laboratory reagents (2013/S 155-270211 - Full names and addresses of all companies who submitted a PQQ and / or ITT for this tender and whether they were successful or not.	09 September 2015	Answered - in full
15/434	Public Assessment report (PAR) and the Risk Management Plan (RMP) for Neupogen (filgrastim), procedure number is UK/H/0019/009	15 September 2015	Answered - in part
15/435	Data for Nortriptyline tablets and Colchicine tablets.	17 September 2015	Answered - in full
15/437	Leucomax embryo-foetal toxicity reports.	15 September 2015	Answered - in full
15/439	Confirm whether Tetralysal was approved on basis of informed consent. Details of reference product and either Public Assessment Report for Tetralysal 300mg hard capsules (PL 10590/0019) or detailed summary of clinical data.	25 September 2015	Answered - in part
15/440	Details of all of the companies who submitted a PQQ and / or ITT for the tender Potters Bar: Repair and maintenance services of generators 2014/S 032-051911 14/02/2014	09 September 2015	Answered - in full
15/441	The date the last licence variation was granted for a Product Licence of Right (PLR).	15 September 2015	Answered - in full
15/442	A redacted copy of any MHRA GMP Inspection Reports issued in the last 3 years for: EASTGATE LABORATORY SERVICES LIMITED QUEEN STREET PLACE, LOUTH, LN11 9BD, United Kingdom	18 September 2015	Answered - in part
15/443	Approved additional risk minimisation materials for Tracleer/Stayveer (bosentan)	01 October 2015	007b. Not held (disposed of/couldn't locate)

<i>FOI no</i>	<i>Subject</i>	<i>Date reply sent</i>	<i>Result of request</i>
15/448	For 13 specified side effects of medication, no. of side effects reported between 01/07/10 and 30/06/15 and; for each, the two drugs with most reported side effects.	05 October 2015	Answered - in full
15/451	Adverse events and investigations arising relating to Valproate use in pregnancy	07 October 2015	Answered - in full
15/452	Water, electricity and gas contracts	17 September 2015	Answered - in full
15/453	The public assessment report for ibuprofen lysine (PL 00327/0125), granted on 27th July 2000? Specifically, were if any efficacy studies were needed to support the approval of this faster acting salt given that the absorption is faster than the free acid form of ibuprofen.	25 September 2015	Answered - in part
15/454	Number of applications approved for importation of unlicensed medicines	18 September 2015	Answered - in full
15/455	MHRA Good Distribution Practice Report for Campdale Pharmaceuticals Ltd	18 September 2015	Answered - in part
15/456	Adverse reactions to breast implants and the side effects for the calendar year 2014.	07 October 2015	Answered - in full
15/457	Out of the 8 intravenous paracetamol solution products authorised in the UK, the no. evaluated for paracetamol dimer oxidative degradation product.	30 September 2015	Answered - in full
	Refers to response to 15/408.		
15/458	Copy of company letter to MHRA of 21/12/2006.	08 October 2015	007b. Not held (disposed of/couldn't locate)
15/460	Each year in the UK, how many people become seriously ill from an adverse reaction, but recover; and how many die?	17 September 2015	007a. Not held (not our info/not collected)
15/461	Related to FOI 15/403. Requests description of tables redacted from linezolid report dated 3 Jan 2007.	07 October 2015	Answered - in full
15/462	Copy of 2015 site inspection cGMP and cGDP at McGregor Cory Ltd, banbury, UK	05 October 2015	Answered - in part
15/464	Related to 15/415 and 15/463. In the instance of mefloquine suicides, how many family members or doctors were contacted by the MHRA?	13 October 2015	Answered - in part
15/466	Concentration of corn syrup in Oramorph Oral Solution 10 mg/5 ml	25 September 2015	Answered - in part
15/468	A copy of the application form submitted by B&S healthcare for the product nortriptyline 25mg tab	23 September 2015	Answered - in part
15/470	Details of any embryo-, foeto- and teratogenic effects reported to be as a result of or likely to be as a result of treatment with Doxorubicin and/or Cyclophosphamide	16 October 2015	Answered - in full
15/471	List of approved Mas for the active substance Pregabalin capsules where neuropathic pain is indicated in the harmonised SPC of Mas approved via MRP/DCP at the end of procedure.	02 October 2015	Answered - in full
15/473	Summary of the risk management plan for Nystan Oral Suspension MA holder E.R. Squibb & Sons PL 0034/0130R	14 October 2015	007a. Not held (not our info/not collected)

<i>FOI no</i>	<i>Subject</i>	<i>Date reply sent</i>	<i>Result of request</i>
15/474	Total ADRs per year (1964 - 2014) broken down by reporter qualification for direct reports and numbers of reactions by reporter qualification	12 October 2015	Answered - in full
15/477	copy of the Clinical Expert Report/Clinical Overview for Prosulf Injection 10mg/ml and Protamine sulphate Injection BP.	12 October 2015	Answered - in part
15/479	Further questions about zyvox, linezolid, and gabriox.	09 October 2015	007a. Not held (not our info/not collected)
15/481	Full details of suspected adverse reaction reports associated with the HPV vaccine in each of the last three full calendar years, and all of 2015 up to the date of this request. For each year the total number of suspected reactions broken down by reaction outcome (i.e recovered, fatal, recovering) In addition, the same information above but only for reactions recorded in Scotland.	26 October 2015	Answered - in full
15/483	Details of the officers responsible for Specialist Consultancy Services.	29 September 2015	Answered - in part
15/485	legal basis for Bedranol SR Capsules 80mg and 160mg and other related questions.	19 October 2015	Answered - in full
15/486	Information relating to banking services, audit services and card processing services.	21 October 2015	Answered - in full
15/487	Information about the Agency's software contract	27 October 2015	Answered - in full
15/489	A copy of a redacted MHRA inspection report and the GMP Certificate	05 October 2015	Answered - in part
15/490	Yellow Card information for all Serious Adverse Events recorded for the HPV Vaccination from 1st July 2015 until	26 October 2015	Answered - in full
15/491	Investigation report on Wockhardt manufactured Amoxicilin.	30th September 2015 08 October 2015	Answered - in part
15/493	The documents, trials and any other supporting evidence which was submitted to the MHRA when the pharmaceutical company Lundbeck were seeking approval for the drug Citalopram to be a prescription drug.	02 November 2015	Answered - in part
15/494	How many women were reported to the MHRA for Citalopram in various categories of pregnancy.	02 November 2015	Answered - in full
15/496	RMP for iron sucrose (Venofer, Vifor Pharma).	03 November 2015	Answered - in part
15/498	The inspection report for Flamingo Pharmaceuticals Ltd.	29 October 2015	007a. Not held (not our info/not collected)
15/500	How many notices or alerts the MHRA issues per year; broken down by Classes 1, 2 and 3 Medical Devices.	03 November 2015	Answered - in part
15/501	Assessment report for the variation for PL 00057/1093.	13 October 2015	007a. Not held (not our info/not collected)
15/502	Breakdown of complaints lodged under "other" category in relation to a table of issues logged in connection with breast implants.	03 November 2015	Answered - in full

<i>FOI no</i>	<i>Subject</i>	<i>Date reply sent</i>	<i>Result of request</i>
15/503	Information relating to Stud 100 Desensitizing Spray for Men.	05 November 2015	Answered - in part
15/505	Copy of the latest GMP inspection report for Mediwin Ltd	26 October 2015	Answered - in part
15/506	An electronic copy of any MHRA GMDP Inspection Reports issued in the last 5 years for CALIGOR RX LIMITED.	03 November 2015	Answered - in part
15/507	An electronic copy of any MHRA GMDP Inspection Reports issued in the last 5 years for MYODERM LIMITED	03 November 2015	Answered - in part
15/508	Last audit for NOVA labs and Novartis Pharmaceuticals.	05 November 2015	Answered - in part
15/509	Information on clinical trials that formed the basis of the national approval of Glypressin.	21 October 2015	Answered - in part
15/510	The naming justification that was submitted in support of the name "Olbas Max Strength All-In-One Cold and Flu Capsules".	09 November 2015	007a. Not held (not our info/not collected)
15/512	CHM report regarding the concern over dose limits for oral Methyl Salicylate	27 October 2015	Answered - in part
15/513	Details of all the import notifications for unlicensed medicines made in the last 6 months to date	02 November 2015	Answered - in full
15/514	Details of adverse incidents involving devices	11 November 2015	Answered - in full
15/518	A list of incidences of progressive multifocal leukoencephalopathy (PML) in multiple sclerosis patients that have been reported to the MHRA in the since 2005.	11 November 2015	Answered - in full
15/520	Non-clinical toxicity data with respect to Lercanidipine.	10 November 2015	Answered - in part
15/521	The number of Yellow Card reports generated by Registered Dental Professionals since 2010	12 November 2015	Answered - in full
15/522	Whether Acetylcysteine 600mg tablets, Acetylcysteine 600mg capsules or Acetylcysteine 600mg eff tabs are in the process of being licensed.	20 October 2015	Answered - in part
15/524	Copy of pages 1-10 of the preliminary renewal assessment report for zyvox/linezolid/gabrix per FOI 08/330.	13 November 2015	007b. Not held (disposed of/couldn't locate)
15/525	Empirical evidence to support MHRA advice to GPs to prescribe antibiotics at a dose independent of body mass	11 November 2015	Answered - in full
15/526	Detailed information on how many cases of drug-induced anaphylaxis are reported to the MHRA annually (types of drugs/outcomes incl fatal/reported by	04 November 2015	Answered - in full
15/527	List of all drugs approved for use in the UK.	11 November 2015	Answered - in full
15/528	Inspection report and license for the Royal Free London NHS Foundation Trust.	16 November 2015	Answered - in part
15/529	Any reports of other people poisoned by ciprofloxacin.	13 November 2015	Answered - in full
15/530	The last 6 months' worth of PV and GCP Inspection reports that had major or critical findings.	17 November 2015	Answered - in part

<i>FOI no</i>	<i>Subject</i>	<i>Date reply sent</i>	<i>Result of request</i>
15/532	Breakdown since 01/01/2010 on the health issues reported of side-effects on the babies of people who had been taking the drug Epilim (Sodium Valproate).	19 November 2015	Answered - in full
15/533	Separate data from reports into incidents connected with alleged side-effects or alleged faults with heart pacemakers for each of the last four financial years.	19 November 2015	Answered - in full
15/535	A copy of the educational material for Levonorgestrel 1.5mg Tablets.	16 November 2015	Answered - in full
15/536	Information relating to contract duration, Start date, Expiry, Review date for National Audit Office.	23 October 2015	007a. Not held (not our info/not collected)
15/538	A copy of the Study Protocol and the Clinical Safety Report for Zyvox or Gabriox and the "Study to Evaluate Eye Function in Patients Taking Linezolid for Six Weeks or Greater.	23 November 2015	Answered - in part
15/539	Various questions about MHRA action taken against online pharmacies accused/suspected of selling dangerous substances.	24 November 2015	Answered - in part
15/540	Details of investigation into a company under Operation Pangea.	16 November 2015	Answered - in part
15/542	A list of business names, addresses and managers/ceo's of every company in the UK that has had an electro-mechanical device cleared for sale in the EU or US in the last 5 years.	02 November 2015	007a. Not held (not our info/not collected)
15/543	If there has ever been an application for a marketing authorisation for oral ivermectin in the UK.	05 November 2015	Answered - in part
15/544	The most current version of the public summary or just the table/overview with the safety concerns for Cipramil-Drops 40 mg/ml, Citalopram hydrochloride, PL0458/0071	25 November 2015	Answered - in full
15/545	Various questions regarding the observed association between narcolepsy and a flu vaccine used during the H1N1v ('swine flu') influenza pandemic.	20 November 2015	Answered - in part
15/548	List of all staff job titles and civil service pay bands.	27 November 2015	Answered - in part
15/549	No. of deaths and complications related to patients undergoing cochlear implant procedure. If poss, names and dates of patients who died/were affected by such implants.	01 December 2015	Answered - in part
15/550	Asks for update on MAAs submitted or granted since previous request for products containing dimethyl fumarate.	04 November 2015	Answered - in part
15/551	What is the lower limit for drug plasma concentrations that relate to ibuprofen's well-defined therapeutic window?	06 November 2015	007a. Not held (not our info/not collected)
15/552	No of suspected adverse reactions (ADRs) for vaccines compiled in the 2014 calendar year, by vaccine. Where fatality involved, name of vaccine and reporter type.	01 December 2015	Answered - in full
15/553	Any information held on the drug, Prometrium (progesterone).	09 November 2015	007a. Not held (not our info/not collected)

<i>FOI no</i>	<i>Subject</i>	<i>Date reply sent</i>	<i>Result of request</i>
15/555	Documents supporting the assignment of a CE mark of conformity to the Oculentis M-Plus multifocal intraocular lens. Who was the notified body; what data was supplied to them; and copies of the clinical data supporting verification of certification.	11 November 2015	007a. Not held (not our info/not collected)
15/559	Correspondence with, including the MHRA's letter and the response from, each of the bodies from the case Mylan and Actavis v Warner Lambert (2015 Ewhc 2548 Pat, 10 September 2015) and internal MHRA documents discussing this issue.	02 December 2015	Answered - in part
15/560	list of all Pharmaceutical Manufacturing companies in the United Kingdom (England, Scotland, Wales, N.I.), stating company name, address, postcode and phone number.	07 December 2015	Answered - in full
15/562	Information on Smith & Nephew BIRMINGHAM HIP REsurfacing Systems CE status 11/2007 for implant, tools and The instructions / safety warnings / involved in all documents	27 November 2015	007a. Not held (not our info/not collected)
15/563	The naming justification that was submitted in support of the name "Covonia Hot Dose Cough & Cold Syrup" for the licence PL 00240/0364? I would just like to understand how this fits into the rest of the Covonia branded products and how this sub-brand is acceptable.	03 December 2015	007a. Not held (not our info/not collected)
15/564	MHRA(MCA) Clinical Assessment Report from the original Marketing Authorisation Applications for APO-go Ampoules 10 mg/ml Solution for Injection (PL 05928/0020) and APO-go pen 10 mg/ml Solution for Injection (PL 05928/0021) as first licensed in 1993.	25 November 2015	Answered - in part
15/565	Disclosure under the Freedom of Information Act of the register the MHRA maintains of all manufacturers selling medical devices in the UK, not merely class 1 medical devices.	11 November 2015	007a. Not held (not our info/not collected)
15/566	Information about the actions of the Committee on Safety of Medicines regarding Sodium Valporate.	19 November 2015	Answered - in full
15/567	comments on draft guidance on Re-manufacture of single use devices.	03 December 2015	Answered - in part
15/568	Information on Serious Adverse Reactions recorded for teenage booster for DTP vaccination	02 December 2015	Answered - in part
15/569	MHRA Inspections of Novartis and Glaxosmithkline Facilities	07 December 2015	007a. Not held (not our info/not collected)
15/571	The total number of spontaneous ADR reports received in 2011, 2012, 2013, and 2014, as well as the number of reports that were reported directly by patients/consumers for each year.	07 December 2015	Answered - in full
15/573	Have MHRA ever inspected HealthCare at Home based in Burton on Trent or any other vendors that are conducting patient support programmes?	04 December 2015	Answered - in full

<i>FOI no</i>	<i>Subject</i>	<i>Date reply sent</i>	<i>Result of request</i>
15/574	Public Assessment Reports and clinical/non clinical overviews and study reports for PANADOL ADVANCE 500mg Tablets and PANADOL ActiFlash 500mg cp.	27 November 2015	007a. Not held (not our info/not collected)
15/575	Information relating to the paper "Bivalent human papillomavirus vaccine and the risk of fatigue syndromes in girls in the UK".	14 December 2015	Answered - in full
15/578	Request for the Assessment report for Merck's Glucophage® Extended Release (XR)'s recent approval for use in more type 2 diabetes patients.	18 November 2015	Answered - in full
15/579	MHRA Inspection of Ipca Laboratories	17 November 2015	Answered - in full
15/583	Various questions regarding Co-proxamol.	16 December 2015	Answered - in full
15/584	Innovator's summary of the Risk management plan levothyroxine.	04 December 2015	Answered - in full
15/586	Request for a list of how many applications were approved for importation of unlicensed medicines for the 12 month period ending 30 June 2014	04 December 2015	Answered - in part
15/587	Critical and Major Pharmacovigilance findings issued by the MHRA	11 December 2015	Answered - in part
15/588	A copy of the annual report provided to the JCVI detailing vaccine-associated suspected adverse reactions for the past year - dated October 2015.	15 December 2015	007a. Not held (not our info/not collected)
15/590	Dosing information on InVita and Thorens.	02 February 2016	Answered - in part
15/591	Marketing information and bioequivalence study of Tamoxifen Teva 20 mg	10 December 2015	Answered - in part
15/592	Information about Mefloquine reactions	21 December 2015	Answered - in full
15/593	The name of the senior service manager from MHRA Head of Service and Commercial Management for Information Management services.	27 November 2015	Answered - in full
15/594	Various questions about Knee Replacement medical device alerts.	14 December 2015	Answered - in part
15/595	Liothyronine - Request for Originator RMP	04 December 2015	Answered - in part
15/596	Nefopam - Request for Originator RMP	08 December 2015	Answered - in full
15/597	Copy of conflicts of interest of experts investigating the MPlus X lens complaints.	24 December 2015	Answered - in full
15/599	MHRA's vehicle, leasing and maintenance contracts.	10 December 2015	Answered - in full
15/600	Latest DAP report regarding the HPV vaccines, Cervarix, Gardasil and other to the end of November 2015.	18 December 2015	Answered - in full
15/601	Questions regarding sexual dysfunction persisting after cessation of SSRI	22 December 2015	Answered - in full
15/603	Adverse incident data for wound care products that utilise negative pressure.	24 December 2015	Answered - in part
15/605	Details of suspected adverse reaction reports associated with the seasonal influenza (flu) vaccine.	04 January 2016	Answered - in full
15/606	Adverse drug reaction reporting information for Docetaxel and Filgrastim'	22 December 2015	Answered - in full

<i>FOI no</i>	<i>Subject</i>	<i>Date reply sent</i>	<i>Result of request</i>
15/607	Marketing information, glycopyrronium bromide 1 & 2mg tablets	09 February 2016	Answered - in part
15/608	Are there any MSC therapies in the process of approval, and if so, how many	10 December 2015	Answered - in full
15/609	Information on certain positions within the Agency.	05 January 2016	Answered - in part
15/610	Has MHRA got any staff who also work for drug companies directly or indirectly	23 December 2015	Answered - in full
15/611	• Who is the senior officer (outside of procurement) responsible for ICT/Digital/Business Change Programmes & Strategy?	08 December 2015	Answered - in full
15/612	Who is the senior officer (outside of procurement) responsible for ICT/Digital/Business Change Programmes & Strategy	18 December 2015	Answered - in part
15/613	Please confirm (or deny) that in 2009 the MHRA granted Boehringer Ingelheim Limited a marketing authorisation ("MA") for the medicinal product Flomax Relief MR, tamsulosin hydrochloride 0.4 mg (reclassification from a prescription-only medicine (POM) to a pharmacy product (P)), and along with such MA the MHRA granted Boehringer Ingelheim Limited additional year of data exclusivity for switches	29 December 2015	Answered - in full
15/614	Correspondence (including any relevant attachments) between the MHRA and the marketing authorisation holder for Risperdal Consta (or its agent) regarding Risperdal Consta and treatment/relief of bipolar disorder or the symptoms/consequences of bipolar disorder.	14 December 2015	Answered - in part
15/615	Are Rouvax (Sanofi Pasteur) or M-Vac (Serum Institute of India) which are unlicensed in the UK tested for safety and purity here in the UK before being administered? (I.e are each batch tested?)	14 December 2015	Answered - in part
15/617	A real case related Article 8 of the convention about real cases.	21 December 2015	007a. Not held (not our info/not collected)
15/619	Assessment Report of products Loestrin 20 and Loestrin 30.	23 December 2015	007b. Not held (disposed of/couldn't locate)
15/620	Yellow card reports on the administration of Pneumococcal Vaccine.	11 January 2016	Answered - in full
15/621	Various questions on staff pay.	13 January 2016	Answered - in full
15/622	Further questions on 23 and Me for the period 2 December 2014 - 14 December 2014.	16 December 2015	007a. Not held (not our info/not collected)
15/624	Request for Accessing Anonymised Yellow Card Scheme Data.	30 December 2015	Answered - in part
15/627	Applications for MA on ecigarettes since 2010.	21 December 2015	Answered - in part
15/628	LAN Maintenance and services	20 January 2016	Answered - in full
15/629	A list of all orthopaedic medical devices withdrawn by the MHRA over the past 15 years.	14 January 2016	Answered - in part

<i>FOI no</i>	<i>Subject</i>	<i>Date reply sent</i>	<i>Result of request</i>
15/630	Information about the withdrawal of Total ankle replacement implants - Ankle Evolutive System (AES) manufactured by Transystème.	22 January 2016	Answered - in part
15/631	Various questions about the structure of the organisation's (MHRA's) IT department.	14 January 2016	Answered - in full
15/633	Information regarding a EURAMOS clinical trial.	11 January 2016	Answered - in part
15/634	ADR/Yellow Card reports submitted in respect of the MMR vaccine batch code HF20080 Merieux.	15 January 2016	Answered - in full
15/638	GMP/GDP Inspection reports for the previous 5 years for the following site: MARINE LIMITED BCB MARINE LIMITED, Clydesmuir Road Industrial Estate, Cardiff, CF24 2QS, 90535-BCB MARINE LIMITED UK WDA(H) 40144	13 January 2016	Answered - in part
15/639	GMP/GDP Inspection reports for the previous 5 years for the following site: ANP PHARMA LIMITED ANP PHARMA LIMITED, 55 HAINAULT ROAD, LONDON, E11 1EA, 9957325-ANP PHARMA LIMITED UK WDA(H) 36080	11 January 2016	Answered - in part
15/640	GMP/GDP Inspection reports for the previous 5 years for the following site: UNIVERSAL MARINE MEDICAL LIMITED UNIVERSAL MARINE MEDICAL LIMITED, UNIT 24A, ROMSEY INDUSTRIAL ESTATE, GREATBRIDGE ROAD, ROMSEY, SO51 0HR, 10438546-UNIVERSAL MARINE MEDICAL LIMITED	11 January 2016	Answered - in part
15/641	GMP/GDP Inspection reports for the previous 5 years for the following site:HUTTON & CO (SHIPS CHANDLERS) LIMITED HUTTON & CO (SHIPS CHANDLERS) LIMITED, DIANTHUS HOUSE, WITTY STREET, HULL, HU3 4TT, 3904595-HUTTON & CO (SHIPS CHANDLERS) LIMITED	15 January 2016	Answered - in part
15/643	The most recent MHRA PV inspection reports for Gilead and Pierre Fabre.	22 January 2016	Answered - in part
15/644	All MHRA pharmacovigilance inspection reports for inspections closed between June 2015 and Dec 2015.	25 January 2016	Answered - in part
15/645	Whether any yellow cards have been reported in respect of adverse drug reactions to the use of Rivaroxaban and any response from the manufacturer.	26 January 2016	Answered - in full
15/646	All information relating to an audit of Silimed's manufacturing processes "which resulted in the suspension of Silimed products".	04 January 2016	007a. Not held (not our info/not collected)
15/647	Lists of Vaccines & drugs that contain Aluminium Hydroxide.	05 January 2016	Answered - in part

<i>FOI no</i>	<i>Subject</i>	<i>Date reply sent</i>	<i>Result of request</i>
16/001	a copy of the Assessment Report for the authorisations for Tarim (oxycodone/naloxone, PL 00289/1974-8) in December 2015.	12 January 2016	Answered - in part
16/002	The inspection agenda and report for the first MHRA Pharmacovigilance Service Provider pilot inspection.	27 January 2016	Answered - in part
16/003	If there are any license applications for disposable e-cigarettes and when they might be expected to be reviewed.	06 January 2016	Answered - in part
16/004	Innovator's summary of the RMP, melphalan	27 January 2016	007a. Not held (not our info/not collected)
16/005	Details of any meetings, emails or other communications between the (MHRA) and British Associated Tobacco (BAT)/Nicovations Ltd concerning the NHS prescribing the 'e-Voke' e-cigarette product and other related questions.	02 February 2016	007b. Not held (disposed of/couldn't locate)
16/006	Information about 'yellow card' reporting of contact lens related corneal ulcers or contact lens related microbial keratitis	03 February 2016	Answered - in part
16/007	Originator RMP for Etonorgestrel & ethinylestradiol Vaginal delivery system 11.7 mg / 2.7 mg	20 January 2016	Answered - in full
16/008	How many notifications and quantities of Bacteriostatic Sodium Chloride 0.9% 30ml manufactured by Hospira has the MHRA received for importation into the UK between 01/01/2013 until 30/06/2015.	26 January 2016	Answered - in full
16/010	Public assessment report for marketing authorization PI 25215/0031	03 February 2016	007a. Not held (not our info/not collected)
16/011	Originator RMP for Buprenorphine-Naloxone	27 January 2016	007a. Not held (not our info/not collected)
16/012	Information relating to Pharmacia products (gabriox, linezolid and zyvox products)	04 February 2016	Answered - in part
16/013	A register of all adverse reactions recorded within the UK, to all immunisations	15 January 2016	007a. Not held (not our info/not collected)
16/015	The last audit for CP PHARMACEUTICALS LIMITED in Wrexham.	01 February 2016	Answered - in part
16/017	Numbers for drugs and homeopathic substances on the market and ADR numbers for both.	05 February 2016	Answered - in full
16/020	List of all staff job titles and civil service pay bands - including division and job title.	29 January 2016	Answered - in full
16/021	Query on a reference product (Multi-Action ACTIFED Dry Coughs)	04 February 2016	Answered - in part
16/022	Information about the WiFi contract.	08 February 2016	Answered - in part
16/023	Have any GMP inspections been carried out at the Croda plant/manufacture in Leek, Staffordshire?	04 February 2016	Answered - in part
16/024	Data for Ethosuximide 250mg Capsules	28 January 2016	Answered - in part

<i>FOI no</i>	<i>Subject</i>	<i>Date reply sent</i>	<i>Result of request</i>
16/026	Validity of National Archives guidance on the disclosure of types of human and veterinary medicines information held by the human and veterinary regulatory authorities	21 January 2016	Answered - in full
16/028	Any PV Inspection reports or inspection data showing the findings (Critical and Major and others) related to the last 3 PV Inspections for 3 pharma companies.	09 February 2016	Answered - in part
16/029	Current status of (i) the reports concerning quality of vision issues some patients have experienced following implantation of the Mplus X multifocal intraocular lens manufactured by Oculentis GmbH	29 January 2016	Answered - in part
16/032	A list of all planned overseas GMP, GDP and PV inspections for 2016	12 February 2016	Answered - in full
16/034	A list of all incidents brought to the attention of the MHRA regarding the sale or supply of senna containing products without a marketing authorisation since January, 2013	15 February 2016	Answered - in full
16/035	Lists of incidents involving children wrongly accessing prescription, pharmacy and general sale medicines and the outcome.	27 January 2016	Answered - in part
16/036	information about legal provsion and spend.	11 February 2016	Answered - in full
16/037	Question about ibuprofen-hyoscine butylbromide.	08 February 2016	007b. Not held (disposed of/couldn't locate)
16/039	Is Marksans Pharma compliant with EU GMP norms and has their site been approved.	12 February 2016	Answered - document/s refused
16/041	Information about Olympus Keymed international and their endoscope products.	16 February 2016	Answered - in part
16/044	Update for 2015 in relation to previous request for listing/output displaying the total number of ADR reports and total number of reactions received across all drugs, year by year (from 1964 to 2014), split between different reporter types (e.g. consumer, physician, pharmacist, etc.).	16 February 2016	Answered - in full
16/045	Details of audits of their contract laboratories	02 February 2016	Answered - in full
16/046	GCP and GVP inspection report(s) (with all critical, major and other deficiencies) and subsequent replies to deficiencies and inspection notes and correspondence to conclusion for the following company: Lambda Therapeutic Research Ltd.,	18 February 2016	Answered - in part
16/050	Latest GMP/GDP inspection reports for the following manufacturing sites: Lonza Biologics, Slough ITH Pharma, London	18 February 2016	Answered - in part
16/052	UKPAR for two Temazepam Oral Solution products.	02 February 2016	007a. Not held (not our info/not collected)

<i>FOI no</i>	<i>Subject</i>	<i>Date reply sent</i>	<i>Result of request</i>
16/053	Seious Adverse Events reports for HPV vaccinations for the period 1 October 2015 to 31 December 2015	23 February 2016	Answered - in full
16/054	Various questions about HPV vaccines.	23 February 2016	Answered - in full
16/055	ADVERTISING OF VOLTAROL EMULGEL PRODUCTS IN THE UK	17 February 2016	Answered - in full
16/057	Stats regarding reports to MHRA regarding anaphylaxis fatalities following immunisations.	22 February 2016	Answered - in full
16/058	Various questions about adjuvant (whooping Cough pertussis) in-conjunction with Anthrax Vaccines.	18 February 2016	007a. Not held (not our info/not collected)
16/059	A copy of the audit report for the GMP audit carried out on 19 March 2015 of Solid Form Solutions Ltd.	24 February 2016	Answered - in part
16/060	Various information in relation to Procedure No: UK/H/5607/001-002/DC and UK Licence No: PL 04569/1149-1450 (Sirdupla 25mcg/125mcg per metered dose inhalation, suspension and Sirdupla 25mcg/250mcg per metered dose inhalation, suspension).	11 March 2016	Answered - in part
16/061	A breakdown of all the alleged side effects reported to MHRA under the yellow card scheme between 1.7.14 and 30.6.15 for Co-Cyprindiol .	16 February 2016	Answered - in full
16/062	UK public assessment report on PL 19494/0063 (Isotrex Gel®)).	02 February 2016	Answered - in full
16/065	legal basis for Gabapentin 50mg/ml Oral Solution and other related questions.	25 February 2016	Answered - in part
16/066	legal basis for Captopril 25mg/5ml and 5mg/5ml Oral Solution and other related questions.	25 February 2016	Answered - in part
16/068	MHRA's report on its good pharmacovigilance practice (GPvP) inspection of Takeda Development Centre Europe Ltd ('Takeda') conducted in 16-19 June 2015	26 February 2016	Answered - in part
16/069	A breakdown of all the alleged side effects associated with Ropinirole reported under the yellow card scheme between 1.7.14 to 30.6.15.	26 February 2016	Answered - in full
16/073	Reason for inconsistent application of exemptions to request for information	11 February 2016	Answered - in full
16/074	UKPAR for Adrenaline (Epinephrine) Injection BP 1 in 1000, subject of PL 01502/0024, issued to Hemaln Pharmaceuticals Ltd on 14th December 1978 last renewed on 23rd August 2001.	02 February 2016	007a. Not held (not our info/not collected)
16/075	Information on the drug Ursodeoxycholic acid (UDCA)	10 February 2016	007b. Not held (disposed of/couldn't locate)
16/077	Copies of assessments undertaken prior to the introduction of meningitis B vaccination into the UK immunisation schedule.	23 February 2016	007a. Not held (not our info/not collected)
16/079	DGRA course "Master of Drug Regulatory Affairs" - authorisation of virulence factor inhibitors	12 February 2016	Answered - in part
16/082	Any reports available from GPvP inspections of contract service providers performed by MHRA.	01 March 2016	Answered - in part
16/083	Country of import of Anoheal (diltazem cream).	02 March 2016	Answered - in full

<i>FOI no</i>	<i>Subject</i>	<i>Date reply sent</i>	<i>Result of request</i>
16/084	Post Market Surveillance Reports.	22 February 2016	Answered - in part
16/085	Where is the scientific data that justifies the use of SSRI's for OCD.	26 February 2016	Answered - in part
16/086	A copy of the amended SPC (s) for Zyvox. In addition did the MHRA review regulatory changes to SPC (s) for Gabriox and Linezolid, (products contain active ingredient linezolid). If not why and please provide the SPCs for Linezolid and Gabriox for the same time period.	16 February 2016	Answered - in part
16/087	The date shown on the letter or email Wockhardt sent to the Agency that was referred to in a letter of 26 jan 2015 (GCEP 00099235) and a copy of that letter.	26 February 2016	Answered - in part
16/088	<ul style="list-style-type: none"> • Did the Medicines and Healthcare Products Regulatory Agency pay for a NLA (Newspaper Licensing Agency) or CLA (Copyright Licensing Agency) media license in 2013-2014? • If so, how much did the Medicines and Healthcare Products Regulatory Agency pay for the licenses in 2013-2014 (please provide the figures separately)? • Did the Medicines and Healthcare Products Regulatory Agency pay for other media licenses in 2013-2014? Please list any other media licenses the council subscribed to and how much was paid for them in 2013-2014. 	04 March 2016	Answered - in full
16/090	Questions around active ingredients/excipients in relation to zyvox, gabriox and linezolid.	03 March 2016	Answered - in full
16/093	What regulations (EU and / or UK) prevent an organization acting as a contract batch certification site only?	03 March 2016	Answered - in full
16/094	Questions about BP having a NLA and CLA Media License?	03 March 2016	Answered - in full
16/095	Copies of all emails and letters sent by the MHRA to the compliants and vigilance manager at Depuy.	28 February 2016	Answered - in part
16/096	Available pharmacovigilance inspection reports in the period 01-Jul-2015 to 31-Jan-2016.	07 March 2016	Answered - in part
16/097	Questions about sourcing of conflict minerals.	16 February 2016	007a. Not held (not our info/not collected)
16/098	Inspection, Mepro Pharmaceuticals	08 March 2016	Answered - in part
16/099	PV reports for various pharma companies	09 March 2016	Answered - in part
16/100	DePuy inspection reports held by the MHRA for the period from 2011 to date	28 February 2016	Answered - in part
16/101	Adverse incidents, Corail/Pinnacle hip system.	28 February 2016	Answered - in part
16/103	Number of hoist deaths each year in the past 10 years and causes.	07 March 2016	Answered - in full
16/105	Metal on Metal hip replacement device alerts in Guernsey.	18 February 2016	Answered - in full
16/107	Information on overdoses on paracetamol	24 February 2016	007a. Not held (not our info/not collected)

<i>FOI no</i>	<i>Subject</i>	<i>Date reply sent</i>	<i>Result of request</i>
16/109	If Company A makes a request for information concerning a medicinal product licenced to Company B, and the information requested is not currently available in the public domain, will the MHRA inform Company B of the request and intended response before providing any information to Company A?	18 February 2016	Answered - in full
16/111	ADR, gillenia	09 March 2016	Answered - in full
16/113	The complete chain of emails from which stephen wilson extracted an email from between the MHRA and the Commissioner dated 23rd October 2009 for FOI request 14/426 regarding a FOI appeal.	01 March 2016	Answered - in full
16/115	UK Public Assessment Report (DCP) for Sativex Oral Mucosal Spray	08 April 2016	Answered - in part
16/116	Adverse drug reactions (ADRs) with Mirabegron.	09 March 2016	Answered - in full
16/117	The PAR of product LEVETIRACETAM 250mg, 500mg, 750, 1000mg.	04 March 2016	Answered - in full
16/118	Pharmacovigilance data for Doxylamine	11 March 2016	Answered - in full
16/119	The last audit for a Glaxo site.	15 March 2016	Answered - in part
16/120	Copies of all ASPreports provided in relation to the following products between 1st March 2011 and 30th September 2015 for CosmoFer, Diafer, Monofer, Venofer and Ferrinject. Plus reports for certain adverse reactions to the products.	15 March 2016	Answered - in part
16/121	UKPAR for below mentioned marketed products: 1. Galfer Syrup (Ferrous fumarate 140mg/5ml) (PL 00240/0106) - Thornton & Ross Ltd 2. Ferrous fumarate 140mg/5ml Oral Suspension (PL 12762/0083) - Mercury Pharmaceuticals Ltd	04 March 2016	007a. Not held (not our info/not collected)
16/123	A month my month printout of all adverse event receives for mefloquine and proguanil.	16 March 2016	Answered - in full
16/124	The letter dated 28th February 2007 from Pfizer limited to healthcare professionals in the UK following safety issues in a study refers to Zyvox tm.	03 March 2016	Answered - in full
16/125	The PAR for Bramox (Midodrine) 2.5 and 5 mg Tablets.	04 March 2016	Answered - in full
16/127	The winning company's submission for a tender on an adverserse drug reaction web form.	14 March 2016	Answered - in part
16/128	Various questions on suspected contraction of Narcolepsy and Cataplexy, following the administering of various Fluenz Influenza vaccines.	16 March 2016	Answered - in full
16/129	the last Pharmacovigilance inspection reports for Gilead, Sigma Tau, Aspen and Daiichi.	17 March 2016	Answered - in part
16/130	Various questions relating to Red Ant Design Ltd and tenders/contracts won at MHRA.	14 March 2016	Answered - in part
16/131	The PV Inspection Report of the MAH "Mylan N.V."	17 March 2016	Answered - in part
16/132	GMP Audit Report for Shasun.	18 March 2016	Answered - in part

<i>FOI no</i>	<i>Subject</i>	<i>Date reply sent</i>	<i>Result of request</i>
16/133	Various questions regarding the MHRA's investigation into the Mplus X Lens.	11 March 2016	Answered - in part
16/137	The annual report provided to the JCVI detailing vaccine-associated suspected adverse reactions for the past year.	22 March 2016	Answered - in full
16/138	Request on new Quality Risk Assessments for Excipients	22 March 2016	Answered - in part
16/139	The study that has enabled the MAH of Propofol to claim a use of lidocaine injection in IV (systemic) with propofol.	22 March 2016	Answered - in part
16/140	All of the pharmaceutical manufacturing companies in the UK that have scheduled MHRA inspections and the dates of those upcoming inspections or audits for 2016/17.	22 March 2016	007a. Not held (not our info/not collected)
16/143	Reports received by the MHRA of adverse sexual effects caused by SSRIs.	14 March 2016	Answered - in full
16/144	A list of all unlicensed medicines which the MHRA has granted import approval in the last 12 months.	23 March 2016	Answered - in full
16/146	Various questions about breaches of the Data Protection Act. (Concerning the CHM).	17 March 2016	Answered - in part
16/147	Various questions about breaches of the Data Protection Act. (Concerning the MHRA).	17 March 2016	Answered - in part
16/148	Various questions about breaches of the Data Protection Act. (Concerning British Pharmacopoea).	17 March 2016	Answered - in part
16/149	Natioonal Health Service Pharmaceutical Quality Assurance Committee minutes, questionnaires to aseptic compounding pharmacies, establishment reports from GMP inspections of sites in the questionnaire and establishment reports for certain hospitals.	24 March 2016	007a. Not held (not our info/not collected)
16/150	When and who from the MHRA provided the letter to (Tsol) in 2013 and which FOI # did it relate to?	01 March 2016	Answered - in full
16/152	Organisational staff details.	30 March 2016	Answered - in part
16/153	All of the Inspection reports from August 2015 to Jan 2016 that had major or critical findings.	30 March 2016	Answered - in part
16/157	What is the process that a company has to go through to be able to trade Homoeopathic Products?	03 March 2016	Answered - in full
16/160	Info relating to number of hospitals within the U.K that currently utilize any type of hemovigilance transfusion system.(Systems to ensure that the correct blood component is transfused into the correct patient).	08 March 2016	007a. Not held (not our info/not collected)
16/161	Il psmf findings identified in pharmacovigilance inspections in 2015 and 2016 with an indication of whether the finding was classed as critical, major and minor	01 April 2016	Answered - in part
16/163	Information about TVT retropubic and TVT Obturator insertion surgery in the UK in the last 10 years	24 March 2016	Answered - in part
16/165	Information about TVT retropubic and TVT Obturator insertion surgery in the UK in the last 10 years	24 March 2016	Answered - in part

<i>FOI no</i>	<i>Subject</i>	<i>Date reply sent</i>	<i>Result of request</i>
16/166	Whether or not Immravax /Trimovax (Merieux) was used in the UK at any time following the 1992 withdrawal.	10 March 2016	Answered - in part
16/167	Various information on: Infliximab, Ustekinumab, Secukinumab and Adalimumab.	09 March 2016	Answered - in part
16/169	Questions about substances marketed as "nootropics" or "smart drugs" and non-medicinal.	07 April 2016	Answered - in full
16/171	Various questions about Natural Desiccated Thyroid.	07 April 2016	Answered - in part
16/172	Various questions about use of and adverse reaction to sterilisation implants.	17 March 2016	007a. Not held (not our info/not collected)
16/173	Update on number of ALCL cases caused by breast implants.	17 March 2016	Answered - in full
16/174	Various questions about Homeopathic Medicine.	10 March 2016	007a. Not held (not our info/not collected)
16/176	A breakdown of all the alleged side effects associated with isotretinoin.	11 April 2016	Answered - in full
16/177	All GMP/GDP Inspection Reports for BUPA Home Healthcare Limited issued in the last 5 years.	12 April 2016	Answered - in part
16/178	Any PV/GCP inspections that have taken place February 2015 to May 2016 resulting in major or critical findings	12 April 2016	Answered - in part
16/179	Pharmacovigilance Inspection reports.	13 April 2016	Answered - in part
16/180	ADR reaction after MMR vaccine in under 5s	13 April 2016	Answered - in full
16/181	Request for Innovator's summary of the RMP, Paracetamol Diphenhydramine	04 April 2016	007a. Not held (not our info/not collected)
16/183	The number of reports, investigations and convictions in to practitioners running bogus botox clinics including via remote prescribing and via the internet.	14 April 2016	Answered - in full
16/184	Public assessment reports for various product licenses	24 March 2016	Answered - in part
16/185	Guidence and regulations MHRA gives to the NHS for the useage of Homoeopathic Products.	21 March 2016	007a. Not held (not our info/not collected)
16/186	Follow up to previous request in respect of a DCP for medicinal products containing glatiramer acetate has recently closing.	11 April 2016	Answered - in full
16/187	Various questions on PIM and EAMS.	18 April 2016	Answered - in part
16/189	A list of medicines that have had either tinnitus or hearing loss reported as a side effect.	18 April 2016	Answered - in full
16/190	Public Assessment Reports for Histalix Syrup, Nicorette 10mg Inhalator, Beechams Max Strength Sore Throat Blackberry Flavour Lozenges.	24 March 2016	007a. Not held (not our info/not collected)
16/192	A copy of the inspection of North China Pharmaceutical Group Semisyntech Co. Ltd.	20 April 2016	Answered - in part
16/193	A redacted copy of the last MHRA inspection report for Millpledge Ltd WDA(H).	21 April 2016	Answered - in part

<i>FOI no</i>	<i>Subject</i>	<i>Date reply sent</i>	<i>Result of request</i>
16/194	How many packs of a product called TAD-600 Glutathione 600mg/4ml 10ampoule pack have been imported into the UK over the previous 12 months or year.	20 April 2016	Answered - in full
16/196	The cost of counterfeit medicines to the UK economy between Jan 2010-Jan 2015 and the pharmaceutical brands most likely to be counterfeited.	14 April 2016	Answered - in part
16/199	Re: FOI 16/144: For each of the products for which at least 100 notifications were received, how many packs were approved?	20 April 2016	Answered - in full
16/201	Environmental risk assessment submitted in support of the application for Equasym (Methylphenidate hydrochloride)	26 April 2016	Answered - in part
16/204	Queries re cost of legal representation	14 April 2016	Answered - in part
16/205	Request for further report - further to FOI 16/153	27 April 2016	Answered - in part
16/211	Various financial information such as Banking, Accountancy and Audit services.	27 April 2016	Answered - in full
16/212	The RMP for paracetamol tablets 500mg.	28 April 2016	Answered - in part
16/214	UKPAR for Trifluoperazine 5mg/5ml Oral Solution.	05 April 2016	007a. Not held (not our info/not collected)
16/215	Various information about the Agency utility supplier contracts.	18 April 2016	Answered - in full
16/218	list of critical products that are allowed to be offered for sale by Marksans Pharma Limited following the issue of a restricted GMP certificate for their plant in Goa.	21 April 2016	Answered - in part
16/220	Type of amber glass bottles used in Sodium Chloride 1 mmol/ml Oral Solution.	21 April 2016	007a. Not held (not our info/not collected)
16/221	The total number of adverse drug reactions (ADRs) reported to you through the Yellow Card scheme in the 2015 calendar year.	28 April 2016	Answered - in full
16/223	Information about MHRA managers who have Government Procurement cards.	05 May 2016	Answered - in full
16/224	Mobile contracts information.	28 April 2016	Answered - in full
16/227	Information about the withdrawal of Co-proxamol and alternative pain management options.	05 May 2016	Answered - in part
16/228	Questionnaires, from July 2014, to aseptic compounding pharmacies, establishment reports from GMP inspections of sites in the questionnaire and establishment reports for certain hospitals.	27 April 2016	Answered - in part
16/229	Various information on LAN contracts.	11 April 2016	Answered - in full
16/230	Information held by the MHRA on the "ARCEQUINE" device technology for human use.	05 May 2016	Answered - in full
16/231	How many adverse incidents reports did the MHRA receive regarding transvaginal mesh tapes for stress urinary incontinence in 2015 .	26 April 2016	Answered - in full

<i>FOI no</i>	<i>Subject</i>	<i>Date reply sent</i>	<i>Result of request</i>
16/232	When the MHRA are going to issue a public health notice for these devices for Stress Urinary Incontinence and when MHRA intend to suspend the use of these mesh tapes.	09 May 2016	Answered - in full
16/235	Public Assessment Report for Copaxone Powder for Injection (PL 10921/0019)	05 May 2016	007a. Not held (not our info/not collected)
16/236	Drug Analysis Print information for different brands of chlorpromazine	11 May 2016	Answered - in full
16/237	Inspection information, Rusan Pharma	28 April 2016	Answered - in full
16/238	Various LAN contract related questions	11 May 2016	Answered - in full
16/239	Re Ibuprofen/Pseudoephedrine Pfizer 200mg/30mg capsules	12 May 2016	Answered - in full
16/240	Public Assessment Report for Lisinopril 5mg/5ml oral solution of MAH: Essential Pharmaceuticals Limited, UK (PL 41094/0010)	05 May 2016	007a. Not held (not our info/not collected)
16/242	Asks whether Agency has no record of advice given to MoD concerning dangers and concerns it raised in 1990.	10 May 2016	Answered - in part
16/244	For last six financial years qs relating to Parallel NICE-MHRA scientific advice for pharmaceuticals	12 May 2016	Answered - in full
16/246	Has a molecule/drug "Cinitapride" been approved or under approval in MHRA UK?	28 April 2016	Answered - in part
16/247	DOXAZOSIN ; Original Human Trial Results for Modified and Immediate Release Versions	11 May 2016	Answered - in part
16/249	All applications for a new license for Liothyronine, either generic or branded and all strengths.	21 April 2016	Answered - in part
16/251	Yellow card information relating to Oculentis Mplus X Intra Ocular Lenses	28 April 2016	Answered - in full
16/252	Names and addresses of Pharma companies inspected for GCP compliance, between 1st July 2013 and 30th June 2014.	18 May 2016	Answered - in full
16/254	Volume of clinical trial authorisations provided each year by MHRA (2012-2016)	13 May 2016	Answered - in part
16/255	Re: PL 00015/0047R - date MA granted; legal basis of application; summary of assessment; summary of clinical data used ot support application	19 May 2016	Answered - in full
16/256	Lisat of products agency granted permission to import as an unlicensed medicinal product in the year 2015 and the number of import notifications received for each unlicensed medicine.	19 May 2016	Answered - in full
16/257	Minutes of CSM Meetings that took place between January 1st 1983 - December 31st 1983 involving in any way, any of the below subjects... AIDS HIV or HTLV-III Factor IIIV Concentrates (Factor 8) Haemophilia Hepatitis A, B or C (Non-A, Non-B)	18 May 2016	Answered - in part

<i>FOI no</i>	<i>Subject</i>	<i>Date reply sent</i>	<i>Result of request</i>
16/258	Latest MHRA audit report for Fine Organics Ltd, Seal Sands, Middlesbrough	20 May 2016	007a. Not held (not our info/not collected)
16/261	The last two Pharmacovigilance inspection reports for Crucell - uk and Johnson and Johnson, High Wycombe.	23 May 2016	Answered - in part
16/262	Why Quotient has been removed from list of Phase 1 trials	16 May 2016	Answered - in part
16/263	Asks if changes in policy result from lobbying by pharmaceutical companies; and whether employees benefit from gifts from companies.	10 May 2016	Answered - in part
16/264	No. of adverse events affecting cardiac rhythm during skin surgery, caused by electromagnetic interference from electrosurgical device.	27 May 2016	Answered - in part
16/267	Potential impact of BREXIT on Agency	24 May 2016	Answered - in full
16/268	Adverse events associated with the use of distal radius locking plates for the last 5 years.	05 May 2016	Answered - in part
16/269	Refers to 16/228. Requests redacted questionnaires and GMP inspection reports for certain facilities.	27 May 2016	Answered - in part
16/271	In relation to a MA, is there an easily accessible document that is provided to the applicant and does not include sensitive data, but refers to the submission date, e.g. MHRA's confirmation of receipt of the MA application? What would be an easy, verifiable and safe way to receive the information on the submission date to the MHRA?	03 May 2016	007a. Not held (not our info/not collected)
16/272	Latest version of the innovator (Evoltra, Genzyme Europe B.V) RMP Part VI Summary of the RMP or the list of safety concerns in relation to Clofarabine.	05 May 2016	007a. Not held (not our info/not collected)
16/273	A copy of the innovator's RMP for enoxaparin to include annexes 7, 10 and 11.	05 May 2016	007a. Not held (not our info/not collected)
16/274	ALL publicly available Product Inserts provided with the said product Myodil for the life of its production.	01 June 2016	Answered - in part
16/275	For each of the last ten years, how many yellow card reports has the agency received of fatal reactions to a statin drug? List by statin.	26 May 2016	Answered - in full
16/276	Identity of complainant	17 May 2016	Answered - in part
16/277	Whether a marketing authorisation for flunarizine has ever been submitted to the MHRA	05 May 2016	Answered - in part
16/278	RMP for Trazodone hydrochloride (UK licence no PL21834/0003 / decentralised procedure UK/H/5221/001/DC).	25 May 2016	Answered - in part
16/281	Information about the number of product imported into the UK which were made available in UK as 'named patient supply'.	27 May 2016	Answered - in full
16/284	Information about hospitality expenses.	03 June 2016	Answered - in full
16/285	When is the MHRA going to publish the results of the toxicology report on mesh implants for SUI and POP?	20 May 2016	007a. Not held (not our info/not collected)

<i>FOI no</i>	<i>Subject</i>	<i>Date reply sent</i>	<i>Result of request</i>
16/286	PAR for Canesten Solution (Clotrimazole 1.0% w/v) Marketing authorisation number: PL 0010/0082 Marketing authorisation holder: Bayer plc	13 May 2016	007a. Not held (not our info/not collected)
16/287	A copy of 'Chandler R E: HPV vaccine and gastrointestinal motility disorders, 2015. Signal - analysis of reports in the WHO Global ICSR Database - V igibase April 2015' actions taken and yellow cards.	07 July 2016	Answered - in full
16/288	No. and types of adverse events associated with the IUD coil by financial year sence 2006 to date	08 June 2016	Answered - in part
16/294	a redacted copy of the MHRA inspection report for Niche Generics Ltd's new procurement site at Arlesley Niche Generics Ltd	19 May 2016	Answered - in part
16/295	Risk management plans for specified Marketing Authorisations.	13 June 2016	Answered - in part
16/297	Complaints/adverse events concerning MMR	14 June 2016	Answered - in full
16/298	UK PARs for:PL 17736/0107 Chemidex Pharma Isosorbide Dinitrate tablets 10mg PL 17736/0108 Chemidex Pharma Isosorbide Dinitrate tablets 20mg PL 00142/0321 Isosorbide Dinitrate tablets BP 10mg (actavis) PL 00142/0322 Isosorbide Dinitrate tablets BP 10mg (actavis	17 May 2016	007a. Not held (not our info/not collected)
16/299	Any literature articles for Brivudine including <ul style="list-style-type: none"> • Safety and tolerability on healthy subjects. • Bioequivalence studies if any. • Public assessment reports and • Any articles regarding clinical trials on Brivudine 	02 June 2016	007a. Not held (not our info/not collected)
16/300	All the clinical advice that MHRA has received relating to the reported issue involving the QRISK@2 Calculator in SystmOne.	13 June 2016	Answered - in full
16/302	A list of all unlicensed medicines for which import notifications have been received by the MHRA in the last 12 months	06 June 2016	Answered - in full
16/303	Sept 2015 GMP inspection report for Pliatus Pharma Ltd, Watford	23 May 2016	Answered - in part
16/305	The last GMP/GDP Inspection reports for Hutton & Co (Ships Chandlers) Ltd, Hull.	10 June 2016	Answered - in part
16/306	The last GMP/GDP Inspection reports for MARINE LIMITED BCB MARINE LIMITED, Cardiff.	13 June 2016	Answered - in part
16/307	Inspection reports for Sandoz and Medreich.	14 June 2016	Answered - in part
16/308	Licensing info for Covonia Cold & Flu Formula	15 June 2016	Answered - in full
16/311	Cannabis oil	22 June 2016	Answered - in full
16/316	Analysis of staff salaries by gender.	20 June 2016	Answered - in full

<i>FOI no</i>	<i>Subject</i>	<i>Date reply sent</i>	<i>Result of request</i>
16/319	An up to date departmental organisation chart for your Communications Directorate showing all positions by job title and number of persons within each post.	02 June 2016	Answered - in full
16/320	Details of payments made (including expenses) to any member of the Scientific Advisory Committee of the NIBSC since 2012	28 June 2016	Answered - in full
16/322	GMP inspection report for: Insp GMP/GDP/IMP 13523/5566-001	10 June 2016	Answered - in part
16/323	CSM Minutes - 1983	27 June 2016	Answered - in part
16/324	NIBSC - Minutes - 1983	30 June 2016	007b. Not held (disposed of/couldn't locate)
16/326	Device information, TOTs and TVTOs.	08 June 2016	007a. Not held (not our info/not collected)
16/329	The PAR/Clinical data for the original Fenbid Gel MA application PL 10972/0045 and Fenbid Forte 10% Gel PL 10972/0082.	24 June 2016	Answered - in part
16/330	The latest GMP Inspection report for Onyx Scientific Ltd	20 June 2016	Answered - in part
16/332	Cases of BIA/ALCL have been reported in the UK	21 June 2016	Answered - in full
16/333	Licensing information, doxorubicin, cisplatin and high dose of methotrexate	06 July 2016	Answered - in part
16/334	The MHRA approved additional risk minimisation materials for Tracleer/Stayveer (bosentan):	07 July 2016	Answered - in part
16/335	HPV	06 July 2016	Answered - in full
16/336	ADRs on PIM drugs and drugs under EAMS	07 July 2016	Answered - in part
16/337	PAR, Dicycloverine 10mg and 20mg Tablets.	30 June 2016	Answered - in part
16/338	Inspection, Cosma Spa, Via Colleoni, 15/17 Ciserano (BG), Bergamo, 24040, Italy	27 June 2016	007a. Not held (not our info/not collected)
16/341	Compromise agreements between Jan 2011 and Dec 2015	08 July 2016	Answered - in full
16/342	Risk Management Plan for product EXTRANEAL (Icodextrin 7.5%) Solution for peritoneal dialysis (PL 00116/0266)	05 July 2016	Answered - in part
16/344	Risk management plans for Perizam and Clobazam products.	13 July 2016	Answered - in part
16/345	PAR, Melphalan 50 mg Powder and Solvent for Solution for Injection/Infusion	20 June 2016	Answered - in part
16/347	Comms division job descriptions and budgets	15 July 2016	Answered - in full
16/349	Correspondence between MHRA and Google/DeepMind and the Royal Free NHS Trust	20 July 2016	Answered - in full
16/357	Clinical info, Nitrofurantoin monohydrate	20 July 2016	Answered - in full
16/358	PV inspections conducted from 31 Mar 14 - 31 Mar 16	29 June 2016	Answered - in full
16/359	ADR, fluoride varnish	22 July 2016	Answered - in full
16/363	Clinical info Ibuleve Speed Relief Gel/Ibuderm	26 July 2016	Answered - in full

<i>FOI no</i>	<i>Subject</i>	<i>Date reply sent</i>	<i>Result of request</i>
16/365	Information on card processing services contracts	21 July 2016	Answered - in full
16/367	PAR of Carbocisteine 2.7g	04 July 2016	Answered - in part
16/368	HPV	26 July 2016	Answered - in full
16/372	Clinical & Non clinical overview: Dexamethasone Tablets BP 2.0mg	13 July 2016	007a. Not held (not our info/not collected)
16/373	RMP & Clin/non clinical overview Lexpec 2.5mg/5ml Oral Solution	15 July 2016	007a. Not held (not our info/not collected)
16/375	MHRA expenditure	04 August 2016	Answered - in full
16/376	Clinical reports, Nurofen, Ibuleve	30 September 2016	Answered - in part
16/377	E-cigarettes notification	08 July 2016	Answered - in full
16/380	Sativex ingredients	20 July 2016	Answered - in full
16/381	Sativex prescriptions 2015	12 July 2016	007a. Not held (not our info/not collected)
16/383	to import Tadalafil tablets	08 August 2016	Answered - in part
16/384	(PSUR) for fluoxetine	05 August 2016	Answered - in part
16/388	Security & Fire products and services	04 August 2016	Answered - in full
16/390	ADR, child vaccines	05 August 2016	Answered - in full
16/391	Educational materials, Bosentan	18 July 2016	Answered - in part
16/392	Data, Ferinject	15 July 2016	Answered - in full
16/393	Insepctions, Dr Reckeweg; Noma Ltd	11 August 2016	Answered - in part
16/394	Inspection, MALLINCKRODT RP UK LIMITED	26 July 2016	Answered - in part
16/395	ADR, wound dressings	11 August 2016	Answered - in part
16/396	list of all companies currently approved to sell/supply antibiotics	24 August 2016	Answered - in full
16/397	Request for any information held on an individual's fitness to practice	01 August 2016	Answered - in part
16/398	Quinacrine	09 August 2016	007a. Not held (not our info/not collected)
16/399	Mefenamic acid clinical trial	01 September 2016	Answered - in full
16/401	Registration procedure of vaccines	26 July 2016	Answered - in full
16/402	MA information on Ketamine	28 July 2016	Answered - in part
16/403	ADR since 2000 in relation to maze Starch Thickeners	05 August 2016	007a. Not held (not our info/not collected)
16/404	Medical Device Vigilance and QMS reports	17 August 2016	Answered - in full
16/406	MA info Medicinal CBD Oil manufactured by CBD Brothers Ltd.	12 August 2016	Answered - in full

<i>FOI no</i>	<i>Subject</i>	<i>Date reply sent</i>	<i>Result of request</i>
16/407	Levothyroxine reference products and clinical summary	03 August 2016	Answered - in full
16/408	Sativex	29 July 2016	Answered - in full
16/409	Inspection, Rusan Pharma	03 August 2016	Answered - in full
16/410	Clinical data, EYEGUARD-B	08 August 2016	Answered - in part
16/411	MHRA Employment agency questions	22 August 2016	Answered - in full
16/412	GMP certificate, Incepta	08 August 2016	Answered - in part
16/414	Expiry dates for medical products	28 July 2016	Answered - in full
16/415	Inspections, GMP and GDP	02 September 2016	Answered - in full
16/416	Reports regarding Oculentis X Lens	28 July 2016	Answered - in part
16/417	ADR, electroconvulsive machines.	28 July 2016	Answered - document/s refused
16/418	ADR, HPV	25 August 2016	Answered - in full
16/419	ADR - Vaccines	23 August 2016	007a. Not held (not our info/not collected)
16/420	Incident report reference 2016/005/028/401/001	25 August 2016	Answered - in part
16/421	Incident report, reference 2016/006/018/401/003	25 August 2016	Answered - in part
16/422	Inspections, GMP and GDP	09 August 2016	Answered - in part
16/423	Inspections, Aurobindo	05 September 2016	Answered - in full
16/425	Inspections with Major or Critical findings	09 August 2016	Answered - in full
16/427	Sativex	03 August 2016	Answered - in full
16/429	DUPLICATE NUMBER- answered under FOI 16/417	29 July 2016	007a. Not held (not our info/not collected)
16/430	Details relating to a recently granted adrenaline MA	12 August 2016	Answered - in part
16/431	Request for updated figures to FOI 16/316	25 August 2016	Answered - in full
16/432	Contact details for blood establishments	09 August 2016	Answered - document/s refused
16/433	FOI - information relating to information linked to complaint	31 August 2016	Answered - in full
16/435	Patient educational and HCP educational materials for Remodulin	12 August 2016	007a. Not held (not our info/not collected)
16/436	Sativex	09 August 2016	Answered - in full
16/440	MHRA Expenditure	05 September 2016	Answered - in full
16/441	Request for data on sexual reactions reported with SSRIs	01 September 2016	Answered - in full
16/442	Inspection report relating to University of Birmingham	06 September 2016	Answered - in full

<i>FOI no</i>	<i>Subject</i>	<i>Date reply sent</i>	<i>Result of request</i>
16/443	Clinical study reports, ezetimibe/simvastatin	06 September 2016	Answered - in full
16/444	Clinical study reports, GLYCOPYRRONIUM BROMIDE	29 September 2016	Answered - in full
16/445	ADR Tazocin trial information	07 September 2016	Answered - in full
16/447	Information regarding CPRD	24 August 2016	Answered - in part
16/449	Request for data about EU/UK drug approvals and financials	06 September 2016	Answered - in part
16/450	Preclinical studies - Timoptol	05 September 2016	Answered - in full
16/451	Questions relating to co-proxamol	22 August 2016	Answered - in full
16/453	Communications between PIP and TUV	01 September 2016	Answered - in full
16/455	Info licensing of sofosbuvir (also known as Sovaldi)	13 September 2016	Answered - in full
16/456	Neupogen Singleject 30 MU	14 September 2016	Answered - in part
16/458	Inspection reports, biosimilar companies	21 September 2016	Answered - in full
16/459	MAs questions on oxycodone	27 September 2016	Answered - in part
16/460	ADRs MedImmune UK intra-nasal seasonal influenza vaccine	16 September 2016	Answered - in full
16/461	info on Project 14:Models of viral hepatitis licence held by NIBSC	27 September 2016	Answered - in part
16/463	PAR Request Pylera	13 September 2016	Answered - in part
16/464	recall of THR Hypericum Products	30 September 2016	Answered - in full
16/465	Details relating to herbal rubs	29 September 2016	Answered - in full
16/466	Formal request of innovator educational materials_daptomycin	20 September 2016	Answered - in full
16/467	copy paper were purchased during the 2015/16 financial year?	06 October 2016	Answered - in part
16/468	Inspection report - BCM limited	30 September 2016	Answered - in full
16/469	Inspection report - 2 Pharmacovigilance Service Providers inspected by the MHRA	06 October 2016	Answered - in full
16/471	Request for safety data relating to Bexsero	05 October 2016	007a. Not held (not our info/not collected)
16/472	Herbal medication (Remens)	28 September 2016	Answered - in part
16/473	organisation's most recently available annual expenditure	04 October 2016	Answered - in full
16/474	Audit report - Quest Healthcare Limited	05 October 2016	Answered - in full
16/475	ADRs vaginal mesh	06 October 2016	Answered - in full
16/476	Request from INFACT - instructions to NHS England re: valproate	06 October 2016	Answered - in full
16/477	Request for information relating to a centralised MA - Feraccru	05 October 2016	Answered - in full
16/479	Information on number of spinal components implanted	20 September 2016	007a. Not held (not our info/not collected)

<i>FOI no</i>	<i>Subject</i>	<i>Date reply sent</i>	<i>Result of request</i>
16/480	Educational materials for Tenofovir Disoproxil, Efavirenz/Emtricitabine/Tenofovir Disoproxil tablets and Tenofovir Disoproxil/Emtricitabine tablets	07 October 2016	Answered - in full
16/482	ADR (Herbals)	13 October 2016	Answered - in full
16/483	UKPAR Diazepam 2mg/5ml Oral Suspension of Sandoz Limited	28 September 2016	007a. Not held (not our info/not collected)
16/485	ADR relating to HPV vaccines (Gardasil, Cervarix and unknown)	17 October 2016	Answered - in full
16/487	CT DATA	13 October 2016	Answered - in full
16/488	Toxicity or safety regarding Shield Therapeutics Feraccru	05 October 2016	Answered - in full
16/489	13 different side effects	17 October 2016	Answered - in full
16/491	Request for data relating to facilities	05 October 2016	007a. Not held (not our info/not collected)
16/493	Adverse reactions related to breast implant surgery	18 October 2016	Answered - in full
16/494	Request for various documents - future plans	19 October 2016	Answered - in full
16/495	Sales data from Viagra and Cialis	04 October 2016	007a. Not held (not our info/not collected)
16/496	Price data for Viagra and Cialis	29 September 2016	007a. Not held (not our info/not collected)
16/497	Request for personal info re: Ian Rees	11 October 2016	Answered - in full
16/498	GMP Inspection report Aesica Pharmaceuticals Limited	17 October 2016	Answered - in full
16/499	HPV data	21 October 2016	Answered - in full
16/502	co-phenotrope - PLAT 4 handle	21 October 2016	007a. Not held (not our info/not collected)
16/504	Nicovations products Voke & EVOKE	21 October 2016	Answered - in full
16/505	Staff expenses	03 October 2016	Answered - in full
16/506	ADR(S) to vaccines	07 October 2016	Answered - in full
16/507	Yellow card - MMR vaccination	26 October 2016	Answered - in part
16/508	Data on Plasmids	20 October 2016	007a. Not held (not our info/not collected)
16/509	ADRs various medications	20 October 2016	Answered - in full
16/510	Inspection report	31 October 2016	Answered - in full
16/511	Minutes of CSM Meetings - HIV Jan to Dec1984	18 October 2016	Answered - in full
16/512	TRIAMAZON clinical trial data	11 October 2016	Answered - in full
16/513	Change to the status of CBD (Cannabidiol)	02 November 2016	Answered - in full
16/514	Expenditure on software for the years 2014/15 and 2015/16	03 November 2016	Answered - in part

<i>FOI no</i>	<i>Subject</i>	<i>Date reply sent</i>	<i>Result of request</i>
16/515	Data to classify CBD products as a "medical product"	04 November 2016	Answered - in full
16/516	MA Propylthiouracil 50mg & Propylthiouracil Tablets BP 50mg	02 November 2016	Answered - in part
16/518	Information on CBD	03 November 2016	Answered - in full
16/520	Minutes & reclassification of Cannabidiol (CBD)	07 November 2016	Answered - in full
16/521	correspondence BHMA & EHTPA or other herbal medicine professional Assoc	13 October 2016	007a. Not held (not our info/not collected)
16/524	DAP reports for the HPV vaccines, Cervarix, Gardasil	26 October 2016	Answered - in full
16/527	organisational chart PLAT 4 & OTC division	04 November 2016	Answered - in part
16/531	ADRs Corn Starch thickeners	07 November 2016	Answered - in full
16/532	Celebrex/Celecoxib - Yellow card reports	10 November 2016	Answered - in full
16/534	Request for three CT reports Braltus to Spiriva	11 November 2016	Answered - in part
16/535	Inspection report, a) Guy's and St Thomas' NHS Foundation Trust's Pharmacy Manufacturing Unit b) Barts Health NHS Trust Pharmacy Manufacturing Unit	14 November 2016	Answered - in part
16/536	Inspection reports - Insp GMP 204/92237-0010 Insp GMP 204/92237-0008	14 November 2016	Answered - in part
16/537	Imatinib Teva UK (the "Product")	01 November 2016	Answered - in part
16/538	ADRs hormonal contraception	11 November 2016	Answered - in full
16/539	Information on Primodos pregnancy tests Jan 1967-Dec 1975	02 November 2016	007a. Not held (not our info/not collected)
16/540	the list of all Pharmacovigilance Inspectors	01 November 2016	Answered - in full
16/541	Inspection reports - Companies with a Major or Critical finding	14 November 2016	Answered - in part
16/542	claims against the organisation - clinical negligence & staff claims	21 October 2016	007a. Not held (not our info/not collected)
16/543	MMR vaccine yellow card submissions	11 November 2016	Answered - in full
16/544	Due diligence on Pharmagate Ltd	20 October 2016	007a. Not held (not our info/not collected)
16/546	Clinical trial data on Fluoxetine	16 November 2016	Answered - in part
16/547	Telecoms and Network Services	17 November 2016	Answered - in full
16/548	ICT information	15 November 2016	Answered - in part
16/551	Inspection reports	18 November 2016	Answered - in part
16/552	SPCs & PILS Sodium Valproate Epilim -1973 to 22.10.2016	17 November 2016	Answered - in full
16/553	RMP Carbimazole tablets in the UK	17 November 2016	Answered - in part

<i>FOI no</i>	<i>Subject</i>	<i>Date reply sent</i>	<i>Result of request</i>
16/554	Inspection report Cipla, Verna, Goa, India	21 November 2016	Answered - in part
16/555	Influenza Vaccine—Fluenzetetra—Trials, Excipients	16 November 2016	Answered - in full
16/556	Names of individuals who work in Policy	16 November 2016	Answered - in part
16/557	Silimed breast implants Risk Analysis report	22 November 2016	007a. Not held (not our info/not collected)
16/561	Inspection report	21 November 2016	Answered - in part
16/565	ADRs specific to Immravax E0028	22 November 2016	Answered - in part